Bruker (NASDAQ:BRKR) Issues Quarterly Earnings Results

Bruker (NASDAQ:BRKR) released its quarterly earnings results on Thursday. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06), FiscalAI reports. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same period last year, the firm posted $0.76 earnings per share. The business’s revenue was down .2% on a year-over-year basis. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• FY2026 guidance — Bruker expects reported revenue of $3.57–$3.60B (4%–5% growth), 1%–2% organic growth, a 250–300 bps non‑GAAP operating margin improvement, and 15%–17% non‑GAAP EPS growth (23%–25% CER), while acknowledging an ~8% currency EPS headwind.
• Strong Q4 cash and deleveraging — Q4 operating cash flow was ~ $230M with free cash flow of $207M, the company repaid ~$145M of debt and finished 2025 with ~ $300M in cash and a leverage ratio of ~3.1.
• Order momentum and strategic wins — BSI book‑to‑bill was >1.0 for two consecutive quarters with ~7 months of BSI backlog, strong semi‑metrology orders, double‑digit spatial biology orders, and >$500M in multi‑year BEST superconducting‑wire agreements booked.
• Lingering headwinds and near‑term weakness — 2025 organic revenue declined (full year down 3.7%, Q4 organic down 5.1%), margins were pressured by tariffs, unfavorable mix and currency (gross margin down ~310 bps in Q4), and management expects Q1 2026 organic revenue to decline mid‑single digits before recovery later in the year.

Bruker Price Performance

Shares of BRKR stock traded down $6.71 during trading hours on Thursday, hitting $35.72. 2,861,274 shares of the company’s stock were exchanged, compared to its average volume of 2,525,314. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22. The stock has a market cap of $5.43 billion, a price-to-earnings ratio of -223.41, a price-to-earnings-growth ratio of 5.47 and a beta of 1.19. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The stock’s 50-day moving average is $47.37 and its 200-day moving average is $40.57.

Insider Activity at Bruker

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $6,319,395.60. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 27.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Several hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Bruker during the 1st quarter worth $262,000. Goldman Sachs Group Inc. boosted its stake in shares of Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after purchasing an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth lifted its stake in Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after buying an additional 6,008 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q4 revenue beat expectations — Bruker reported $977.2M in revenue vs. consensus of $964.6M, showing top-line resilience. Bruker’s (NASDAQ: BRKR) Q4 CY2025 sales beat estimates
• Positive Sentiment: FY2026 revenue guidance raised/confirmed aboveStreet — company set FY revenue around $3.6B, above consensus ~ $3.5B, which supports growth expectations for the year. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Commercial partnership in India expands spatial biology footprint — a collaboration with Premas Life Sciences may help adoption and revenue growth in a key market. Premas Life Sciences Partners with Bruker Spatial Biology to Strengthen Advanced Tissue Research in India
• Neutral Sentiment: Revenue was essentially flat year-over-year (down ~0.2%), indicating stability but limited organic growth in the quarter. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company posted materials (press release, slide deck, conference call) for deeper review — useful for investors but not market-moving by itself. View Press Release / Slide Deck
• Negative Sentiment: EPS missed and profitability weakened — Q4 EPS $0.59 vs. consensus $0.65 and down from $0.76 a year ago; net margin was slightly negative, which pressured investor confidence. Bruker (BRKR) Q4 Earnings Miss Estimates
• Negative Sentiment: FY2026 EPS guidance came in slightly below consensus — management guided EPS of $2.10–$2.15 versus street ~ $2.13, which, combined with the EPS miss, likely amplified the selloff despite the revenue guidance. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Market reaction: high volume selling — investors appear to have focused on the EPS miss and the modest EPS guidance shortfall, driving a sharp decline in the share price. (See company filings and coverage above for details.)

Analysts Set New Price Targets

BRKR has been the subject of several research analyst reports. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. JPMorgan Chase & Co. boosted their price target on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group increased their target price on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Barclays boosted their price target on shares of Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, The Goldman Sachs Group began coverage on Bruker in a report on Tuesday, December 9th. They issued a “sell” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $53.23.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.